Login to Your Account

HIV heats up as BMS pipeline goes to Viiv in multibillion-dollar deal

By Marie Powers
News Editor

Friday, December 18, 2015

Bristol-Myers Squibb Co. (BMS) exited development of HIV therapies in a big way, selling its entire R&D pipeline of HIV assets to erstwhile competitor Viiv Healthcare Ltd., the joint venture established in 2009 by GSK and Pfizer Inc. to focus on HIV medicines.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription